Recent Pfizer Press Releases
Pfizer Celebrates 10th Anniversary of this Signature Social Investment Program
(BUSINESS WIRE)--Pfizer Inc. is proud to celebrate the 10th anniversary of its Global Health Fellows Program (GHF) as part of its corporate social investment strategy that focuses on leveraging the full range of the company's resources -- people, medicines, expertise and funding -- to broaden access to medicines and strengthen health care delivery for underserved people around the world. GHF is Pfizer's signature corporate volunteer program that pairs
more...
(BUSINESS WIRE)--Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union (EU) for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated
more...
The First Once-Daily, Extended-Release Liquid Medication for the Treatment of ADHD is Now Available in Pharmacies
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD). Quillivant XR is the first once-daily, extended-release liquid methylphenidate for ADHD and is now available by prescription. "In order to effectively treat patients with chronic conditions such as
more...
Prevenar 13 is the First and Only Pneumococcal Conjugate Vaccine Approved for This Age Group
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved expanding the use of the company's pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae. Children in this
more...
The majority of patients found Rebif Rebidose easy to use in a user trial
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Rebif® Rebidose® (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20130103/SF36310LOGO) (Logo: http://photos.prnewswire.com/prnh/20121220/SF32295LOGO-b) (Logo: http://photos
more...
ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin in Three Key Outcomes—Stroke and Systemic Embolism, Major Bleeding and All-Cause Mortality—for Patients with Nonvalvular Atrial Fibrillation
ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin in Three Key Outcomes—Stroke and Systemic Embolism, Major Bleeding and All-Cause Mortality—for Patients with Nonvalvular Atrial Fibrillation
more...